These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1391 related items for PubMed ID: 17275230

  • 1. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J, Lee A, Lu Y, Lee RJ.
    Int J Pharm; 2007 Jun 07; 337(1-2):329-35. PubMed ID: 17275230
    [Abstract] [Full Text] [Related]

  • 2. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
    Jung SH, Jung SH, Seong H, Cho SH, Jeong KS, Shin BC.
    Int J Pharm; 2009 Dec 01; 382(1-2):254-61. PubMed ID: 19666094
    [Abstract] [Full Text] [Related]

  • 3. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
    Ogawara K, Un K, Tanaka K, Higaki K, Kimura T.
    J Control Release; 2009 Jan 05; 133(1):4-10. PubMed ID: 18840484
    [Abstract] [Full Text] [Related]

  • 4. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J, Li C, Guo W, Li Y, Wang C, Zhang L, Zhang L, Hao Y, Wang Y.
    J Control Release; 2007 Apr 02; 118(2):204-15. PubMed ID: 17239468
    [Abstract] [Full Text] [Related]

  • 5. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
    Wu J, Lu Y, Lee A, Pan X, Yang X, Zhao X, Lee RJ.
    J Pharm Pharm Sci; 2007 Apr 02; 10(3):350-7. PubMed ID: 17727798
    [Abstract] [Full Text] [Related]

  • 6. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome.
    Xiao W, Chen X, Yang L, Mao Y, Wei Y, Chen L.
    Int J Pharm; 2010 Jun 30; 393(1-2):119-26. PubMed ID: 20416367
    [Abstract] [Full Text] [Related]

  • 7. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S.
    Cancer Chemother Pharmacol; 2010 May 30; 66(1):43-52. PubMed ID: 19779718
    [Abstract] [Full Text] [Related]

  • 8. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice.
    Yamada A, Taniguchi Y, Kawano K, Honda T, Hattori Y, Maitani Y.
    Clin Cancer Res; 2008 Dec 15; 14(24):8161-8. PubMed ID: 19088031
    [Abstract] [Full Text] [Related]

  • 9. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X, Wang X, Wang Y, Yang L, Hu J, Xiao W, Fu A, Cai L, Li X, Ye X, Liu Y, Wu W, Shao X, Mao Y, Wei Y, Chen L.
    J Control Release; 2010 Jul 01; 145(1):17-25. PubMed ID: 20307599
    [Abstract] [Full Text] [Related]

  • 10. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR, Paliwal R, Pal HC, Saxena AK, Sharma PR, Gupta PN, Agrawal GP, Vyas SP.
    Mol Pharm; 2012 Jan 01; 9(1):176-86. PubMed ID: 22091702
    [Abstract] [Full Text] [Related]

  • 11. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
    Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A.
    Clin Cancer Res; 2000 May 01; 6(5):1949-57. PubMed ID: 10815920
    [Abstract] [Full Text] [Related]

  • 12. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
    Paliwal SR, Paliwal R, Mishra N, Mehta A, Vyas SP.
    Curr Cancer Drug Targets; 2010 May 01; 10(3):343-53. PubMed ID: 20370682
    [Abstract] [Full Text] [Related]

  • 13. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
    Sun M, Wang Y, Shen J, Xiao Y, Su Z, Ping Q.
    Nanotechnology; 2010 Nov 26; 21(47):475101. PubMed ID: 21030757
    [Abstract] [Full Text] [Related]

  • 14. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
    Wong HL, Rauth AM, Bendayan R, Wu XY.
    Eur J Pharm Biopharm; 2007 Mar 26; 65(3):300-8. PubMed ID: 17156986
    [Abstract] [Full Text] [Related]

  • 15. Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes.
    Han HD, Lee A, Hwang T, Song CK, Seong H, Hyun J, Shin BC.
    J Control Release; 2007 Jul 31; 120(3):161-8. PubMed ID: 17524514
    [Abstract] [Full Text] [Related]

  • 16. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
    Zhang C, Zhao L, Dong Y, Zhang X, Lin J, Chen Z.
    Eur J Pharm Biopharm; 2010 Sep 31; 76(1):10-6. PubMed ID: 20472060
    [Abstract] [Full Text] [Related]

  • 17. Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia.
    Gaber MH.
    J Biochem Mol Biol Biophys; 2002 Oct 31; 6(5):309-14. PubMed ID: 12385965
    [Abstract] [Full Text] [Related]

  • 18. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
    Wang JC, Liu XY, Lü WL, Lee HS, Goh BC, Zhang Q.
    Yao Xue Xue Bao; 2005 May 31; 40(5):475-80. PubMed ID: 16220797
    [Abstract] [Full Text] [Related]

  • 19. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
    Abu Lila AS, Kizuki S, Doi Y, Suzuki T, Ishida T, Kiwada H.
    J Control Release; 2009 Jul 01; 137(1):8-14. PubMed ID: 19285528
    [Abstract] [Full Text] [Related]

  • 20. Biodistribution of ascorbyl palmitate loaded doxorubicin pegylated liposomes in solid tumor bearing mice.
    Jukanti R, Devraj G, Shashank AS, Devraj R.
    J Microencapsul; 2011 Jul 01; 28(2):142-9. PubMed ID: 21265713
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.